Miltefosine for Mucosal Leishmaniasis

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Completed

Looking for future studies?

Key information

Conditions

Leishmaniasis Euglenozoa Infections Infections Parasitic Diseases Protozoan Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Parasitic Skin and Connective Tissue Diseases Vector Borne Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Palos Blancos, Bolivia

About this study

Treat bolivian mucosal leishmaniasis with miltefosine.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Mucosal leishmaniasis

Exclusion criteria

Abnormal liver function tests (LFT)
Abnormal kidney function test
Concomitant diseases

Treatment and study plan

miltefosine 2.5 mg/kg/day for 28 days

Drug

Primary outcomes

Efficacy

Secondary outcomes

toxicity

Sponsors and collaborators

Lead sponsor

AB Foundation

Other

Registry information

Important dates

Study start: 2004
Study completion: 2006
First posted: Sep 8, 2006
Registry last updated: Sep 8, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed